Enrollment starts in Ph 2 Stenoparib trial in Advanced Ovarian Cancer Patients
”The intensive review and finalization of this new protocol, with feedback from the FDA, the IRB and our treating physicians marks a critical milestone in our effort to accelerate stenoparib as a potentially safer, more effective alternative to additional lines of chemotherapy,” said Thomas Jensen, CEO of Allarity Therapeutics. “Importantly, this new protocol simultaneously allows us to accelerate the development of stenoparib alongside the stenoparib-DRP as a companion diagnostic. Pushing both in parallel will generate the critical data needed to support timely, connected regulatory approval for both. We are very excited about the thoughtful, unique design of this new protocol as it allows us to quickly and effectively get stenoparib into the hands of the world’s best gynecologic oncologists, benefiting patients who need safer and more effective treatment options than the toxic chemotherapy options they would otherwise have to rely upon. We are particularly excited about the prospects of this trial advancing stenoparib’s journey toward commercialization.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
